Inactive Instrument

Fresenius SE & Co. KGaA Share Price Other OTC

Equities

FSNUY

US35804M1053

Healthcare Facilities & Services

Financials

Sales 2024 * 22.19B 24.04B 1,890B Sales 2025 * 23.33B 25.28B 1,987B Capitalization 15.5B 16.8B 1,321B
Net income 2024 * 1.41B 1.53B 120B Net income 2025 * 1.74B 1.88B 148B EV / Sales 2024 * 1.26 x
Net Debt 2024 * 12.44B 13.48B 1,059B Net Debt 2025 * 11.7B 12.68B 997B EV / Sales 2025 * 1.17 x
P/E ratio 2024 *
11.1 x
P/E ratio 2025 *
8.81 x
Employees -
Yield 2024 *
3.43%
Yield 2025 *
3.78%
Free-Float 73.04%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 55 11/04/21
Director of Finance/CFO 44 31/12/18
Compliance Officer - 17/07/23
Members of the board TitleAgeSince
Director/Board Member 69 19/05/15
Chairman 69 31/12/19
Director/Board Member 64 15/07/07
More insiders
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows: - dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.; - hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.; - perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc. Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).
Calendar
More about the company